Long COVID-19 [11C]CPPC Study

Description

The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with history of COVID-19 infection, with and without symptoms. The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with history of COVID-19 infection and still exhibiting symptoms or healthy patients with history of COVID-19 infection but exhibiting no current symptoms.

Conditions

COVID Long-Haul

Study Overview

Study Details

Study overview

The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with history of COVID-19 infection, with and without symptoms. The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with history of COVID-19 infection and still exhibiting symptoms or healthy patients with history of COVID-19 infection but exhibiting no current symptoms.

A Phase l Study to Assess the Safety and Tolerability of PET Imaging With [11 C]CPPC [5-cyano-N-( 4-( 4-[l l CJ me1hylpiperazin-l-yl)-2-(Piperidin-l-yl)Phenyl)Furan-2-carboxamide] Radioligand and Magnetic Resonance (MR) Imaging in Patients With Long COVID.

Long COVID-19 [11C]CPPC Study

Condition
COVID Long-Haul
Intervention / Treatment

-

Contacts and Locations

Baltimore

Johns Hopkins Outpatient Center, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Have the ability to understand the requirements of the study, provide written informed consent, understand and provide written authorization for the use and disclosure of Protected Health Information (PHI) \[per Health Insurance Portability and Accountability Act (HIPAA) Privacy Ruling\] and comply with the study procedures.
  • 2. Documented history of COVID infection at least 6 - 12 months before enrollment.
  • 3. Men and women at least 18 years old.
  • 4. Women must have a negative serum pregnancy test and practice an acceptable method of contraception or be of non-childbearing potential (post-menopausal for at least 2 years or who have undergone hysterectomy, oophorectomy or surgical sterilization).
  • 5. Geographic accessibility to the study center and the ability to travel to the clinic for study visits.
  • 6. Agrees to the visit schedule as outlined in the informed consent.
  • 7. Pre-study labs within normal range, or if abnormal, deemed not clinically significant by the site investigator.
  • 1. History of recent nosocomial infection.
  • 2. History of chronic neurological disorder, such as epilepsy, or structural Central Nervous System (CNS) abnormality such as stroke or arteriovenous malformation.
  • 3. History of head trauma with prolonged loss of consciousness (\>10 minutes) or any neurological condition including stroke, seizure (excluding childhood febrile seizure), or visible structural abnormality on prior MRI.
  • 4. Active or recent (in the past year) substance dependence (drugs-including nicotine, marijuana or alcohol).
  • 5. Receipt of any investigational drug, device or biologic within 30 days of administration of study compound.
  • 6. Use of anti-inflammatory medications, immunosuppressants, or benzodiazepines within 7 days of administration of study compound.
  • 7. Any concomitant medical disease or condition limiting the safety to participate including, but not limited to:
  • * Coagulopathy
  • * Active infection
  • 8. Contraindications to MRI scanning to include pacemakers, metallic implants/prosthesis or prohibitive claustrophobia, etc.
  • 9. Contraindications to PET scanning to include pregnancy, etc.
  • 10. Any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject.
  • 11. Any radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem.
  • 12. Any history of learning disability or special education (due to the potential to affect performance on neuropsychological testing).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Johns Hopkins University,

Licia Luna, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2025-04-30